PeptiDream Inc. is a biopharmaceutical company founded in employing our proprietary Peptide Discovery Platform System PDPS , a state of the art highly versatile discovery platform which enables the production of highly diverse trillions non standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide based, small molecule based, or peptide drug conjugate based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.
Quote | PeptiDream Inc (OTCMKTS:PPTDF)
Last: | $9.50 |
---|---|
Change Percent: | 0.0% |
Open: | $9.5 |
Close: | $9.50 |
High: | $9.5 |
Low: | $9.5 |
Volume: | 205 |
Last Trade Date Time: | 03/22/2024 03:00:00 am |
News | PeptiDream Inc (OTCMKTS:PPTDF)
2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...
Alnylam reported second quarter results that included modest outperformance in product revenue, including 12% qoq growth in Onpattro. 2022 should be a big year for the ATTR-CM program, with APOLLO-B results and a possible early look at HELIOS-B. Intellia's NTLA-2001 showed encoura...
Message Board Posts | PeptiDream Inc (OTCMKTS:PPTDF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
PeptiDream Inc Company Name:
PPTDF Stock Symbol:
OTCMKTS Market:
NEW HAVEN, Conn., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific mo...
NEW HAVEN, Conn., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, announced that it will present data on KPMW135, a novel CD3 x CD20 bispecific mol...
NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc. , a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, today announced the presentation of proof-of-concept data on KPMW101, an anti-tum...